TRU Stock Overview
Develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, Eastern Europe, the Middle East/North Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TruScreen Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.021 |
| 52 Week High | NZ$0.03 |
| 52 Week Low | NZ$0.015 |
| Beta | -0.039 |
| 11 Month Change | 5.00% |
| 3 Month Change | 31.25% |
| 1 Year Change | -4.55% |
| 33 Year Change | -73.75% |
| 5 Year Change | -79.00% |
| Change since IPO | -85.00% |
Recent News & Updates
Shareholder Returns
| TRU | NZ Medical Equipment | NZ Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 0.1% |
| 1Y | -4.5% | 31.5% | 9.6% |
Return vs Industry: TRU underperformed the NZ Medical Equipment industry which returned 31.5% over the past year.
Return vs Market: TRU underperformed the NZ Market which returned 9.6% over the past year.
Price Volatility
| TRU volatility | |
|---|---|
| TRU Average Weekly Movement | 13.7% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in NZ Market | 9.3% |
| 10% least volatile stocks in NZ Market | 3.0% |
Stable Share Price: TRU's share price has been volatile over the past 3 months compared to the NZ market.
Volatility Over Time: TRU's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Martin Dillon | truscreen.com |
TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, Eastern Europe, the Middle East/North Africa, and internationally. The company offers the TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to Truscreen Group Limited in August 2020.
TruScreen Group Limited Fundamentals Summary
| TRU fundamental statistics | |
|---|---|
| Market cap | NZ$12.16m |
| Earnings (TTM) | -NZ$2.05m |
| Revenue (TTM) | NZ$2.60m |
4.5x
P/S Ratio-5.7x
P/E RatioIs TRU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRU income statement (TTM) | |
|---|---|
| Revenue | NZ$2.60m |
| Cost of Revenue | NZ$1.44m |
| Gross Profit | NZ$1.16m |
| Other Expenses | NZ$3.22m |
| Earnings | -NZ$2.05m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 44.75% |
| Net Profit Margin | -78.80% |
| Debt/Equity Ratio | 0% |
How did TRU perform over the long term?
See historical performance and comparison